Dr. Agustin Garcia, M.D.
Claim this profileUniversity Medical Center New Orleans
Studies Breast Cancer
Studies Tumors
9 reported clinical trials
18 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
ER negative
2Tumors
HER2 positive
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Agustin Garcia, M.D. is currently running
Risk-Based Screening
for Breast Cancer
Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called "overdiagnosis"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of "overdiagnosis." This study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive. For participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines. If this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.
Recruiting1 award N/A4 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
More about Agustin Garcia, M.D.
Clinical Trial Related8 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Agustin Garcia, M.D. has experience with
- Paclitaxel
- Trastuzumab
- Nab Paclitaxel
- Nivolumab
- DF1001
- Ladiratuzumab Vedotin
Breakdown of trials Agustin Garcia, M.D. has run
Breast Cancer
Ovarian Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Agustin Garcia, M.D. specialize in?
Agustin Garcia, M.D. focuses on Breast Cancer and Tumors. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Agustin Garcia, M.D. currently recruiting for clinical trials?
Yes, Agustin Garcia, M.D. is currently recruiting for 4 clinical trials in New Orleans Louisiana. If you're interested in participating, you should apply.
Are there any treatments that Agustin Garcia, M.D. has studied deeply?
Yes, Agustin Garcia, M.D. has studied treatments such as Paclitaxel, Trastuzumab, Nab paclitaxel.
What is the best way to schedule an appointment with Agustin Garcia, M.D.?
Apply for one of the trials that Agustin Garcia, M.D. is conducting.
What is the office address of Agustin Garcia, M.D.?
The office of Agustin Garcia, M.D. is located at: University Medical Center New Orleans, New Orleans, Louisiana 70112 United States. This is the address for their practice at the University Medical Center New Orleans.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.